(December 28, 2017) Progress is being made every day, and scientists are on the threshold of many more important discoveries – but we need your help to continue investing in cutting-edge research that will one day lead to a cure, and to keep fighting on Capitol Hill for policies that help women receive the highest … Continued
(December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian cancer patients without BRCA mutations. The research was funded in part by an OCRFA grant to Rugang, Zhang, PhD. PARP inhibitors have already been approved … Continued
(December 14, 2017) For over two decades, you have made it possible for OCRFA to fund the most innovative and promising science, resulting in research breakthroughs that have advanced our understanding of ovarian cancer, how it starts and new treatment options, and you have enabled OCRFA to successfully advocate for federal research dollars and provide … Continued
(December 11, 2017) A study by the Ovarian Tumor Tissue Analysis Consortium, published in JAMA Oncology, looked at the association between cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) and overall survival with certain types of ovarian cancer. After an immunohistochemical analysis of 5,577 patients, researchers saw a strong correlation between high levels of CD8+ TILs and longer … Continued
(December 8, 2017) The results of the CONCORD-2 study, recently published in Cancer, show a large difference in ovarian cancer survival between black women and white women, and also between stages at diagnosis. The data collected from the study, the largest of its kind, looked at 172,849 cases of ovarian cancer, over the course of … Continued
(December 4, 2017) The results of a phase II trial, which focused on stages IIB to IVA epithelial ovarian cancer, were recently published in the Annals of Oncology. The primary purpose of the six year, two stage, multicenter trial was to look at the nine month progressive disease rate when using intraperitoneal (IP) chemotherapy after … Continued
Turn Up the Heat is a foodie’s paradise, featuring treats and libations from more than 50 incredible local women chefs, mixologists, and restaurateurs. Join us on Wednesday, March 7th at the Ronald Reagan Building and International Trade Center in Washington, DC to support Ovarian Cancer Research Alliance. Until December 1st, when you buy a General … Continued
(November 22, 2017) A recent paper published in the Journal of Clinical Investigation reports that a subset of ovarian cancers reduce the expression of a critical gene involved in recycling the cells’ proteins, known as ubiquitin B (UBB). Silencing the expression of a closely related gene, also in the ubiquitin family, that performs an identical … Continued
(October 30, 2017) Until recently, it was thought that high-grade serous ovarian carcinomas (HGSOCs) arose from the ovarian surface epithelium, but recent data from two studies published in Nature Communications suggest that all high grade serous ovarian cancers do in fact originate in the fallopian tube. These findings have implications for ovarian cancer detection and … Continued
(October 20, 2017) An international, large scale study may have found a link between high-grade ovarian cancer and a type of white blood cell known as a tumor-infiltrating lymphocyte. Recently published in JAMA Oncology, the article from the Ovarian Tumor Tissue Analysis Consortium discussed the study, which involved about 5,500 patients, 3,196 of whom had … Continued
(October 19, 2017) BRCA1 and BRCA2 are among the most frequently mutated genes in ovarian cancer. Studies conducted in the past two decades have shown that BRCA1 and BRCA2 play an essential role in protecting DNA from lesions that can lead to tumor formation. However, the factors that cause DNA lesions in BRCA1- and BRCA2-deficient … Continued
(October 13, 2017) The National Comprehensive Cancer Network currently recommends that early stage Ovarian Clear Cell Cancers be treated with adjuvant chemotherapy, or therapy given after the primary treatment as a way to lower the risk of recurrence. However, a retrospective study published recently in Annals of Oncology found that treating stage I endometrioid epithelial … Continued
Get email updates about research news, action alerts, and ways to join the fight.
